Odonate Therapeutics, Inc. Common Stock
ODT was delisted on the 14th of January, 2022.
82 hedge funds and large institutions have $818M invested in Odonate Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 43 increasing their positions, 14 reducing their positions, and 9 closing their positions.
207% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 14
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
6% more funds holding
Funds holding: 77 → 82 (+5)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
28% less capital invested
Capital invested by funds: $1.14B → $818M (-$322M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.61M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.54M |
| 3 |
D.E. Shaw & Co
New York
|
+$2.35M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.19M |
| 5 |
Two Sigma Investments
New York
|
+$1.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$7.98M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.49M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$4.28M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$3.12M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.51M |
ODT Hedge Fund Activity: Q3 2019 in Review
82 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q3 2019, worth a combined $818M — down 28% from $1.14B a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ODT positions and 9 closed out — a net gain of 6 holders — while 43 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $9.61M. The largest seller was Franklin Resources, cutting an estimated $7.98M.
- 82 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q3 2019, up from 77 in Q2 2019.
- Funds reported $818M of Odonate Therapeutics, Inc. Common Stock stock for Q3 2019, down 28% quarter-over-quarter.
- 15 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q3 2019 and 9 closed out, a net change of +6 holders.
- The largest Odonate Therapeutics, Inc. Common Stock buyer in Q3 2019 was BlackRock, an estimated $9.61M added.
- The largest Odonate Therapeutics, Inc. Common Stock seller in Q3 2019 was Franklin Resources, an estimated $7.98M sold.
Based on aggregated 13F filings for Q3 2019.